Bayer Just Won a Supreme Court Battle. The War Ends on July 9.

The numbers tell a story of euphoria — and a market that may be getting ahead of itself. Bayer’s stock has surged 34.56% over the past 30 days, with a single-day jump of over 17% on June 25, the biggest one-day gain since 2003. At €47.35, the shares trade just 5% below their 52-week high of €49.93. Yet the Relative Strength Index sits at 78.7 — deep into overbought territory — and annualized 30-day volatility stands at a jittery 58.49%. The rally has been spectacular, but the underlying story is far from settled.

The catalyst was a landmark decision by the U.S. Supreme Court. By a 7-2 vote on June 25, the justices ruled that federal law preempts state-level warning requirements for glyphosate. Because the Environmental Protection Agency classifies the herbicide as non-carcinogenic, plaintiffs can no longer bring “failure-to-warn” claims based on stricter state labels. That ruling cuts the legal foundation out from under a large chunk of the roughly 61,000 to 65,000 pending lawsuits Bayer faces over its Roundup product.

To cap the fallout, Bayer has put a $7.25 billion settlement on the table — proposed in February 2026 and provisionally approved in March. A hearing on the deal is set for July 9, 2026. If approved, that would cap the company’s total Roundup-related payouts at well over $10 billion, including the more than $10 billion already disbursed to plaintiffs worldwide. The new settlement would also dramatically shrink the pool of active cases, assuming plaintiff attorneys don’t find alternative legal avenues around the EPA’s safety classification.

The ruling strengthens Bayer’s negotiating hand considerably. Institutional investors, many of whom shunned the stock due to unpredictable legal liabilities, now have a reason to take a fresh look. If management can lock in the $7.25 billion settlement swiftly, the freed-up balance sheet capacity could be directed toward debt reduction and operational turnaround. Technically, the shares are firmly above their 200-day moving average of €36.77, confirming that the long-term uptrend is intact.

Should investors sell immediately? Or is it worth buying Bayer?

But the technical picture also flashes warnings. In just seven days after the ruling, the stock climbed 22.8% — and the RSI of 78.7 signals a market that is overheated. The high volatility underlines persistent nervousness. If the July 9 hearing is delayed or the settlement collapses, a sharp pullback toward €40 is a realistic scenario. The rally has priced in a clean resolution, leaving little room for setbacks.

There is also a lingering shadow: the International Agency for Research on Cancer continues to classify glyphosate as “probably carcinogenic.” That classification fuels ongoing political and regulatory debate, even if the Supreme Court ruling blocks state-level warning requirements for now. The legal victory does not end the broader controversy, but it does remove the most damaging class of litigation.

Looking ahead, the immediate focus is on the €49.93 mark — the 52-week high. A clean break above that level would require confirmation from the settlement hearing and, ultimately, a final agreement. Beyond that, investors will want to see concrete targets for dividend policy or debt paydown at the next quarterly results. Such signals would turn a bounce into a genuine revaluation.

Bayer at a turning point? This analysis reveals what investors need to know now.

For now, Bayer has achieved a historic legal win. The bigger test comes on July 9, when the fate of the $7.25 billion settlement becomes clearer. Until then, the stock carries a dual risk: the possibility that the settlement fails, and the reality that the rally has already pulled forward many of the gains. The war of attrition in the courtroom may be shifting in Bayer’s favor, but the financial battle is only entering its next phase.

Ad

Bayer Stock: New Analysis - 30 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER | boerse | 69660763 |